[2-(Imidazol-1-yl)methyl-4-[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonylamino]acetyl]phenyl]oxyacetic acid trifluoroacetate | 197237-35-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: [2-(Imidazol-1-yl)methyl-4-[[[4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonylamino]acetyl]phenyl]oxyacetic acid trifluoroacetate
• 英文别名: 2-[2-(Imidazol-1-ylmethyl)-4-[2-(4,5,6,7-tetrahydrothieno[3,2-c]pyridine-2-carbonylamino)acetyl]phenoxy]acetic acid;2,2,2-trifluoroacetic acid
• CAS: 197237-35-7
• 化学式: C₂HF₃O₂*C₂₂H₂₂N₄O₅S
• 分子量: 568.53
• InChiKey: DTMQJQDXPDMPTF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.35
• 重原子数：
  39
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  188
• 氢给体数：
  4
• 氢受体数：
  13

文献信息

• NOVEL HETEROCYCLIC COMPOUNDS HAVING PLATELET AGGREGATION INHIBITORY EFFECTS
  申请人：MEIJI SEIKA KABUSHIKI KAISHA

  公开号：EP0897920A1

  公开（公告）日：1999-02-24

  Disclosed are a compound represented by the following formula (I) and pharmacologically acceptable salt and solvate thereof having inhibitory activity against platelet aggregation:    wherein A represents the following formula (II), (III), or (IV): A pharmaceutical composition comprising the above compound can be utilized as a platelet aggregation inhibitor that possesses excellent inhibitory activity against platelet aggregation, is free from hemorrhage and other side effects such as those derived from selectivity for the inhibitory action, and is potent against vasculature lesions, such as vasospasm.

  本发明公开了具有血小板聚集抑制活性的下式(I)代表的化合物及其药理学上可接受的盐和溶液： 其中 A 代表下式 (II)、(III) 或 (IV)： 由上述化合物组成的药物组合物可用作血小板聚集抑制剂，该药物对血小板聚集具有极佳的抑制活性，无出血和其他副作用，如抑制作用的选择性所产生的副作用，并对血管痉挛等血管病变具有强效作用。